Plate Nº 53 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Semaglutide Extended Mouse Lifespan by Nearly 100 Days, NIH-Funded Study Finds
Semaglutide, the active ingredient in Ozempic, extended lifespan by nearly 100 days in aging mice and beat calorie restriction on memory and blood sugar, an NIH-funded Nature study finds.
By Elena Vasquez4 min read735 words
In brief
- Semaglutide extended median lifespan by nearly 100 days in older female mice (Nature, Sept. 12, 2026).
- The study compared semaglutide with a 24% calorie-restricted diet over five months in 20-month-old mice.
- Treated mice improved in spatial memory, exploratory behavior, and blood sugar control beyond calorie restriction.
- UC Berkeley researchers led by Danica Chen conducted the NIH-funded study (NIA grants R01AG063404 and others).
- Human effects remain unproven; further clinical research is required.
Older mice receiving semaglutide lived a median of nearly 100 days longer than untreated animals, according to an NIH-funded study published September 12, 2026, in Nature. The drug — the active ingredient in Ozempic and Wegovy — also improved memory, muscle function, and several biological markers of aging, and in some measures it appeared to beat calorie restriction, the gold-standard lifespan intervention in lab animals.
Researchers led by Danica Chen, Ph.D., professor of metabolic biology and nutrition at the University of California, Berkeley, carried out the work with support from three grants from the NIH's National Institute on Aging. Their results raise the possibility that GLP-1 drugs act on the biological machinery of aging itself — though the findings come from mice, not people.
What did the researchers actually test?
The team gave semaglutide to 20-month-old female mice — animals in which aging was already well underway — for three months. That timing matters: most longevity research focuses on interventions started early in life, while this study asked whether the drug could still help late in the game.
Compared with untreated mice, the semaglutide group showed:
- Better muscle function
- Better cognitive performance
- Improved blood sugar control
- Reduced inflammation, measured through gene activity
- Less decline in the body's capacity to repair and regenerate tissue
In a separate group that received the drug until death, median lifespan was nearly 100 days longer than in untreated controls.
Was it just eating less?
Semaglutide suppresses appetite, so an obvious explanation is that the mice simply ate fewer calories — and calorie restriction is famously good at extending lifespan in laboratory animals. Chen's team designed a direct comparison to rule this out.
For five months, one group of 20-month-old female mice received semaglutide while another group followed a 24% calorie-restricted diet matched to what the treated mice were eating. Many effects looked similar between the two groups, and most physiological measurements stayed stable. But semaglutide pulled ahead in several areas:
- Treated mice improved beyond their starting levels in exploratory behavior and spatial memory
- They maintained blood sugar better
- Their metabolic rate stayed largely unchanged, while metabolism slowed in the calorie-restricted animals
Chen said these differences carry a clear implication. "These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction," she said. "Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions."
In plain terms, the drug may not merely mimic a sparse diet — it may engage a separate, still-unidentified biological route linked to longevity.
Why does this matter for human medicine?
Earlier animal studies have shown that GLP-1 drugs can delay the onset of multiple age-related diseases. If semaglutide works on the underlying mechanisms of aging, that could help explain why this class of drugs has shown benefits across such a wide range of conditions, from diabetes to cardiovascular disease.
Rafael de Cabo, Ph.D., a senior investigator at the NIH's National Institute on Aging who wrote a commentary on the study, put it plainly: "Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you'd expect to see."
Can Ozempic slow human aging?
Not yet proven — and the researchers say so directly. The study involved female mice only, and mouse findings often fail to translate to people. The results do not show that Ozempic, Wegovy, or any other GLP-1 drug extends human lifespan.
Some early human signals exist, including a recent post-hoc analysis of the SLIM LIVER trial, but far more clinical research is needed to establish whether these drugs can meaningfully influence human aging or longevity. Chen noted that future clinical studies may examine the drugs in healthy older adults; if similar benefits appear in people without obesity or diabetes, the potential uses of GLP-1 treatments could broaden considerably.
For now, the takeaway is measured: a widely used diabetes and weight-loss drug has shown genuine anti-aging effects in mice, outperforming calorie restriction on several measures, and it may work through a previously untapped biological pathway. Whether that pathway exists in humans — and whether it can be safely harnessed — is the question longevity researchers will now chase.
via nature.com (Original)
More from Elena Vasquez
Nearby plates
- Lancet Publishes Results of Semaglutide Trials in Early Alzheimer's
- One Immune Receptor May Drive Aging Throughout the Body
- Muscle-Sparing Antibody Halves Lean Mass Loss from Semaglutide
- Large Nordic Study Finds No Link Between Semaglutide and Pancreatic Cancer
- Quitting Ozempic for Two Years Raises Heart Risk by 22%